HR+/HER2- breast cancer
Oncology · 2005–2025
31decisions
12medicines
18carried consumer input
155individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| ribociclib Adjuvant treatment of hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), resected early breast cancer (eBC) at high… | Jul 2025 | Not recommended | input received Medical Oncology Group Australia · Rare Cancers Australia · Breast Cancer Network Australia · Inherited Cancers Australia · Medical Oncology Group |
| elacestrant Estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) locally advanced or metastatic breast cancer with activating ESR1… | Mar 2025 | Not recommended | 1 individuals Rare Cancers Australia · Breast Cancer Network Australia · Medical Oncology Group |
| capivasertib Treatment of locally advanced or metastatic hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer with… | Nov 2024 | Not recommended | input received Rare Cancers Australia · Breast Cancer Network Australia · Medical Oncology Group |
| ribociclib Adjuvant treatment of hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), axillary lymph node positive, invasive,… | Nov 2024 | Recommended with restriction | input received Medical Oncology Group · Rare Cancers Australia · Inherited Cancers Australia · Breast Cancer Network Australia |
| sacituzumab govitecan Treatment of adult patients with unresectable locally advanced or metastatic hormone receptor positive (HR+), human epidermal growth factor receptor 2 (HER2)… | Jul 2023 | Not recommended | input received Medical Oncology Group |
| abemaciclib Adjuvant treatment of hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), lymph node positive, invasive, resected early… | Mar 2023 | Recommended with restriction | 2 individuals Medical Oncology Group · Breast Cancer Network Australia |
| abemaciclib Adjuvant treatment of hormone receptor positive, HER2-negative, lymph node positive, invasive, resected early breast cancer at high risk of disease recurrence,… | Nov 2023 | Recommended with restriction | input received Medical Oncology Group · Special Interest Group · Breast Cancer Network Australia · MOGA Breast Cancer Special Interest Group |
| sacituzumab govitecan Treatment of adult patients with unresectable locally advanced or metastatic hormone receptor positive (HR+), human epidermal growth factor receptor 2 (HER2)… | Nov 2023 | Not recommended | input received Consumer Group · Breast Cancer Network Australia |
| abemaciclib Adjuvant treatment of hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-), lymph node positive, invasive, resected,… | Mar 2022 | Not recommended | input received Breast Cancer Network Australia · Medical Oncology Group |
| palbociclib Treatment of patients with locally advanced (stage IIIB/IIIC) or metastatic (stage IV) hormone receptor positive (HR+), human epidermal growth factor receptor… | Mar 2022 | Recommended with restriction | unclear |
| palbociclib Locally advanced or metastatic hormone receptor-positive, HER2-negative breast cancer in combination with an aromatase inhibitor or fulvestrant. | Jul 2021 | Recommended with restriction | input received Rare Cancers Australia |
| abemaciclib Treatment of non-premenopausal patients with hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) inoperable locally… | Mar 2021 | Recommended with restriction | 3 individuals Breast Cancer Network Australia · Medical Oncology Group |
| fulvestrant First-line and second-line endocrine-based treatment of patients with non-premenopausal, hormone receptor positive (HR+) and human epidermal growth factor… | Jul 2020 | Recommended with restriction | unclear |
| ribociclib First- and second-line treatment in combination with fulvestrant for non-premenopausal patients with hormone receptor positive (HR+), human epidermal growth… | Jul 2020 | Deferred | input received Breast Cancer Network Australia · Medical Oncology Group |
| ribociclib Treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) unresectable advanced or metastatic… | Nov 2020 | Recommended with restriction | 1 individuals Medical Oncology Group |
| abemaciclib Initial endocrine-based treatment for non-premenopausal patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative… | Mar 2019 | Deferred | 1 individuals Breast Cancer Network Australia · Medical Oncology Group |
| palbociclib Treatment of non-premenopausal patients with HR+/HER2- locally advanced inoperable breast cancer and metastatic breast cancer in combination with a… | Mar 2018 | Recommended with restriction | none received |
| ribociclib Hormone receptor positive, human epidermal growth factor receptor 2 negative locally advanced inoperable or metastatic breast cancer in postmenopausal women as… | Mar 2018 | Recommended with restriction | none received |
| ribociclib First-line endocrine-based treatment of non-premenopausal patients with hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative… | Jul 2017 | Not recommended | 1 individuals Breast Cancer Network Australia · Medical Oncology Group |
| palbociclib Initial endocrine-based therapy in postmenopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-)… | Mar 2017 | Not recommended | 6 individuals Breast Cancer Network Australia · Medical Oncology Group |
| palbociclib Non pre-menopausal patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 (HER2-) negative locally advanced inoperable breast… | Nov 2017 | Not recommended | 115 individuals Breast Cancer Network Australia · Medical Oncology Group |
| ribociclib First-line endocrine-based treatment of postmenopausal patients with hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative… | Nov 2017 | Not recommended | 25 individuals Breast Cancer Network Australia · Medical Oncology Group |
| everolimus Treatment of post-menopausal women with hormone-receptor positive, HER2 negative advanced breast cancer in combination with exemestane after failure of… | Jul 2013 | Recommended | no section in document |
| everolimus Treatment, in combination with an aromatase inhibitor, of post-menopausal women with hormone-receptor positive, HER2 negative advanced breast cancer after… | Mar 2013 | Not recommended | unclear |
| letrozole Extended adjuvant treatment of hormone-dependent early breast cancer in post-menopausal women who have completed standard adjuvant therapy with tamoxifen… | Mar 2007 | Recommended with restriction | no section in document |
| exemestane Sequential adjuvant treatment of hormone-dependent early breast cancer in post-menopausal women following a minimum of 2 years of tamoxifen therapy. | Jul 2006 | Recommended with restriction | no section in document |
| exemestane Sequential adjuvant treatment of hormone-dependent early breast cancer in post-menopausal women following a minimum of 2 years treatment with tamoxifen citrate. | Jul 2006 | Recommended with restriction | no section in document |
| letrozole Treatment of hormone-dependent breast cancer in post-menopausal women, including early adjuvant and extended adjuvant settings. | Jul 2006 | Recommended with restriction | no section in document |
| docetaxel Adjuvant treatment of node-positive breast cancer in combination with an anthracycline and cyclophosphamide. | Mar 2006 | Recommended with restriction | no section in document |
| anastrozole Treatment of hormone-dependent early breast cancer in postmenopausal women. | Jul 2005 | Recommended | no section in document |
| letrozole Extended adjuvant treatment of early-stage hormone-dependent breast cancer in post-menopausal women who have completed no less than 4.5 years of standard… | Nov 2005 | Not recommended | no section in document |
Who spoke
Medical Oncology Group · Breast Cancer Network Australia · Rare Cancers Australia · Inherited Cancers Australia · Special Interest Group · MOGA Breast Cancer Special Interest Group · Medical Oncology Group Australia · Consumer Group
What the PBS pays
$372M in government benefit over 2024–25, across 869,123 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| abemaciclib | $109.2M |
| ribociclib | $109.1M |
| palbociclib | $76M |
| sacituzumab govitecan | $30.8M |
| everolimus | $23M |
| docetaxel | $4.9M |
| Letrozole | $4.6M |
| letrozole | $4.6M |
| fulvestrant | $3.8M |
| exemestane | $3.4M |
| anastrozole | $2.4M |
Appraised elsewhere
NICE, in England and Wales, has appraised 17 technologies for this condition, recommending 13 and declining 2. A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| imlunestrantImlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy (terminated evaluation) | TA1168 | terminated | 2026-06 |
| sacituzumab govitecanSacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more treatments (terminated appraisal) | TA1089 | terminated | 2025-08 |
| ribociclibRibociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive HER2-negative early breast cancer at high risk of recurrence | TA1086 | recommended restricted | 2025-08 |
| capivasertibCapivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment | TA1063 | recommended | 2025-05 |
| olaparibOlaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy | TA1040 | recommended | 2025-02 |
| elacestrantElacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment | TA1036 | recommended | 2025-02 |
| palbociclibPalbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA836 | recommended restricted | 2022-10 |
| alpelisibAlpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer | TA816 | recommended restricted | 2022-08 |
| abemaciclibAbemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence | TA810 | recommended | 2022-07 |
| abemaciclibAbemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA725 | recommended restricted | 2021-09 |
| ribociclibRibociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA687 | recommended restricted | 2021-03 |
| abemaciclibAbemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer | TA563 | recommended restricted | 2019-02 |
Showing the 12 most recent of 17.
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| alpelisibPIQRAY alpelisib 200 mg daily dose blister (200 mg tablet) | 2020 | 4 |
| inavolisibITOVEBI inavolisib 3 mg film-coated tablet blister pack | 2025 | 2 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 18 of 22 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.